BRAF and thyroid gland undifferentiated (anaplastic) carcinoma: Consider it necessary to examine these two molecular pathways for anaplastic thyroid carcinoma because BRAF and MEK inhibitors have been shown beneficial in treating anaplastic thyroid carcinoma in numerous prior clinical trials [39].